Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
2.800
+0.090 (3.32%)
Oct 4, 2024, 4:00 PM EDT - Market closed

Company Description

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.

Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.

The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer.

Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Marker Therapeutics, Inc.
Marker Therapeutics logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Juan Vera

Contact Details

Address:
9350 Kirby Drive, Suite 300
Houston, Texas 77054
United States
Phone 713 400 6400
Website markertherapeutics.com

Stock Details

Ticker Symbol MRKR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001094038
CUSIP Number 57055L107
ISIN Number US57055L2060
Employer ID 88-0277072
SIC Code 2834

Key Executives

Name Position
Dr. Juan F. Vera M.D. Co-Founder, Chief Executive Officer, President, Treasurer, Secretary and Director
Elizabeth Donnelly Director of Administration
Dr. Maria-Bernadette Madel Director of Corporate Operations and External Communications
Edmund Cheung Vice President of Human Resources
Dr. Monic Stuart M.D. Chief Medical Officer
Patricia Allison Head of Clinical Operations
Mary Newman Ph.D. Head of Regulatory Affairs
Dr. Robert Z. Florkiewicz Sr. Senior Director of Molecular Biology and Virology

Latest SEC Filings

Date Type Title
Aug 14, 2024 8-K Current Report
Aug 14, 2024 10-Q Quarterly Report
Aug 12, 2024 8-K Current Report
Jun 12, 2024 8-K Current Report
May 17, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
May 15, 2024 8-K Current Report
May 15, 2024 10-Q Quarterly Report
Apr 26, 2024 ARS Filing
Apr 26, 2024 DEF 14A Other definitive proxy statements
Apr 8, 2024 8-K Current Report